News

XOMA Royalty Corporation will acquire Generation Bio for $4.2913 per share in cash, plus a contingent value right that...

Humacyte has published the first prospective long-term outcomes for its off-the-shelf biologic vascular conduit, Symvess, in extremity arterial trauma,...

Galapagos released topline data from two phase 3-enabling studies of its oral, selective TYK2 inhibitor GLPG3667. In dermatomyositis, the...

Scilex Holding Company has opened the claim process for its Dream Bowl 2026 Meme Coin, a token distribution to...

Galapagos will wind down its cell therapy business following a strategic review and reported a nine‑month 2025 net loss...

Aquestive Therapeutics is steering its sublingual epinephrine candidate, Anaphylm, toward a potential U.S. launch in the first quarter of...

Revolution Medicines advanced its RAS(ON) portfolio with multiple late-stage moves: global enrollment is winding down for Rasolute 302, the...

ADMA Biologics posted third-quarter 2025 revenue of $134.2 million, up 12% year over year, with GAAP net income of...

Cytek Biosciences posted third-quarter 2025 revenue of $52.3 million, up 2% year over year, and expanded its installed base...

Kymera Therapeutics has completed enrollment and dosing in its Phase 1b BROADEN study of KT-621, a first-in-class, once-daily oral...